Plinabulin and one or more G-CSF drugs are used for treating a chemotherapy induced neutropenia, stimulating neutrophil survival, reducing bone pain induced by the G-CSF drug and alleviating immune suppression effect induced by the G-CSF drug. For example, docetaxel-induced neutropenia can be reduced by-co-administering plinabulin and one or more G-CSF compounds.

Provided herein are substituted piperazine compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

The present disclosure provides a compound of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

The present disclosure provides a compound of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

The present disclosure discloses sodium ion channel inhibitors, pharmaceutically acceptable salts and polymorphs thereof, and uses thereof. Specifically, the present disclosure discloses a polymorph of a compound of formula (X) and a preparation method thereof. The preparation method of the present disclosure is simple in operation and suitable for industrialization. The polymorph prepared by the preparation method has advantages of good stability, low hygroscopicity and high water solubility.

##STR00001##

A process for preparing a diazabicyclooctane compound represented by the following formula (I): ##STR00001##
wherein A represents RcO; B represents NH or NC.sub.1-6 alkyl; C represents a benzyl group; Rc represents a C.sub.1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): ##STR00002##
wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

Electrolytes comprising at least one lithium salt and at least two ionic liquids, at least one of which is an ionic liquid resulting from the association of at least one cation complying with the following formula (I):

##STR00001##

In which: R.sup.1 is an acyclic hydrocarbon group; n is an integer ranging from 0 to 3; m is an integer ranging from 1 to 4; and at least one Y anion.

The present invention provides oxalic amide ligands and uses thereof in copper-catalyzed coupling reaction of aryl halides. Specifically, the present invention provides a use of a compound represented by formula I, wherein definitions of each group are described in the specification. The compound represented by formula I can be used as a ligand in copper-catalyzed coupling reaction of aryl halides for the formation of CN, CO and CS bonds. ##STR00001##

The present invention provides oxalic amide ligands and uses thereof in copper-catalyzed coupling reaction of aryl halides. Specifically, the present invention provides a use of a compound represented by formula I, wherein definitions of each group are described in the specification. The compound represented by formula I can be used as a ligand in copper-catalyzed coupling reaction of aryl halides for the formation of CN, CO and CS bonds. ##STR00001##